Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis
PEDIATRIC INFECTIOUS DISEASE JOURNAL(2008)
摘要
Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT): 4.5].
更多查看译文
关键词
respiratory syncytial virus,social risk,palivizumab,cost-effective analysis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要